Obesity drug race heats up with multi-hormone combos

The gist

Pharma giants are turbocharging the obesity drug race with multi-hormone combos that promise double the weight loss of old-school GLP-1s.

What to know

  • Eli Lilly’s triple-action retatrutide posted about 28% body weight loss in early trials, outstripping single-pathway rivals like Ozempic.
  • Only 10–11 million of 100–130 million eligible US patients are on branded GLP-1s, leaving a massive addressable market.
  • Pharma licensing deals hit a ten-year high at $232B in 2025, as Pfizer and Sanofi snap up late-stage obesity assets with billion-dollar bets.

Hormone Stacking Raises the Bar

Drugmakers are racing to outdo single-pathway obesity drugs by stacking multiple hormone targets, with early data showing combination therapies can double weight loss compared to Ozempic.

The mechanism race in obesity is no longer about a stronger GLP-1 alone; it is about stacking pathways to beat single-agent results. In the “Triumph” studies, early readouts for Eli Lilly’s retatrutide — a triple agonist combining GLP-1, GIP and glucagon signaling in one drug — were described as “about 28.3% total body weight loss,” versus “about 15% total body weight loss” for semaglutide and “approximately 22%” for tirzepatide, while Business Insider framed a head-to-head result even more bluntly: “Eli Lilly’s Retatrutide Trims 44-47 lb, Doubling Ozempic’s 21-lb Loss in Head-to-Head Trial.” That head-to-head result was positioned as evidence that multi-mechanism obesity drugs can outperform single-agent GLP-1 therapy on weight loss, reinforcing the broader combination-pathway strategy.

That same logic is spreading beyond triple agonists into other hormone pairings, as companies test whether mixing mechanisms can preserve efficacy while improving how patients tolerate and stay on treatment. CNBC reported, “Eli Lilly’s eloralintide-tirzepatide combo cuts 23% body weight in Phase 2 trial,” a reported Phase 2 result that supports the mechanism claim that companies are pursuing multi-hormone combinations — pairing amylin-based biology with GLP-1/GIP pathway activity — to improve obesity treatment. Meanwhile, Amgen is pursuing its own multi-hormone approach by combining GLP-1 pathway activation with GIP pathway blockade: MariTide “acts as a GLP-1 agonist… and gastric inhibitory polypeptide (GIP) antagonist,” a design Amgen said produced average weight loss of around 20% after a year, compared with about 15% for the highest semaglutide dose.

Sources

Obesity Gold Rush Intensifies

Despite blockbuster headlines, most eligible patients remain untreated, fueling a surge of billion-dollar licensing deals and aggressive pipeline bets from pharma giants.

The obesity market looks crowded in headlines but underpenetrated in practice, which is why companies are still chasing a wide open patient pool rather than fighting over a fully enrolled one. Eli Lilly CEO Dave Ricks said a Gallup poll found 11% of Americans are currently on these medicines and called the category “still very nascent,” arguing GLP-1 adoption remains limited and is not expected to reach broad, full-population uptake. He added that roughly 10 to 11 million people used branded GLP-1s in September out of 100 million to 130 million eligible patients, or only about 8% to 9% of the addressable population, framing current branded GLP-1 usage as low relative to the eligible population and reinforcing substantial remaining demand beyond early adopters.

That remaining runway is also visible in how capital is being deployed: IQVIA said licensing reached a ten-year high of roughly $232 billion in 2025, with clinical-stage programs taking a larger share as buyers targeted assets with clearer development paths. The same logic shows up in deal structure and pipeline spending, from Pfizer paying 3SBio $1.25 billion upfront for rights to SSGJ 707 outside China while leaving the company intact, to Sanofi paying $600 million upfront for DR-0201 via an asset-centered subsidiary deal, and Pfizer launching ten Phase 3 trials for a monthly obesity shot.

Sources
BiotechTV - NewsBowTiedBiotechYahoo Finance

Get the stories behind the trends

Deep-dive reporting and the weekly brief, in your inbox.